Dear Chris: In my experience CD5+23+19+ & generally (but not exclusively) reduced intensity light chain helps key out a CLL by immunophenotype. The absence of CD23 expression with the same immunophenotype (and more light chain expression) would suggest a mantle cell. I have not personally found FMC7 a very useful reagent. regards frederic preffer At 06:44 PM 6/12/97 -0500, you wrote: > > >Melissa -- > >According to the FAB group (Bennett JM, et al, J. Clin. Pathol. 1989; >42:567-584), the incidence at which FMC7 is positive in >30% of cells in >intermediate lymphocytic lymphoma (ie, Mantle Cell lymphoma) is 40-80%; in >CLL, it is 10-40%. > >Our lab here in Scottsdale does not use FMC7; our panel resembles what Hugh >Johnson has listed in his message earlier. We found that the addition of CD23 >sometime ago has facilitated identification of early (leukemic) presentations >of MCL (CD5+/CD23-). These cases probably account for as many as 5-10% of our >clonal B cell lymphoid leukemia patients. I would, however, add something to >what Maryalice and Hugh have stated: the relative *intensity* of sIg and CD20 >expression can be extremely helpful in distinguishing between MCL and CLL. MCL >(and other NHL) are typically bright CD20+ and bright kappa (or lambda) >positive, while CLL shows dim/weak expression for these markers. > >What do some other folks have to say about panels in the workup of chronic >lymphoid leukemias? (Randy Gascoyne? Curt Hanson?) > >*************************************************************** >Christopher R. Conley, MD conley.christopher@mayo.edu >Dept. of Pathology Tel:(602)301-8021 FAX:(602)301-8372 >Mayo Clinic Scottsdale 13400 E. Shea Blvd. Scottsdale AZ 85259 > > ```````````````````````````````````````````` Dr. Frederic I. Preffer preffer@helix.mgh.harvard.edu Department of Pathology- Warren 525A 100 Blossom St Massachusetts General Hospital Boston MA 02114 v(617) 726-7481 fax(617) 724-3164
This archive was generated by hypermail 2b29 : Wed Apr 03 2002 - 11:49:51 EST